Greater interest in the biotech sector
There was a positive flow of capital into the biotech sector during the third quarter.BB Biotech is actively increasing its exposure to new drug development technology such as RNA-based therapeutic agents, and gene and cell-based therapies.
Biotech outlook: Increasing strength of innovation in 2018
2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and our holdings in focus. We continue to expect new product launches and their uptake in the market to accelerate the already positive underlying growth in revenues and cash flows experienced by the industry and companies in our portfolio.
BB Biotech – double digit return and record dividend
With a total return of 23.1% in CHF BB Biotech delivered a strong performance in 2017. A record regular dividend of CHF 3.30 per share will be proposed at the AGM.
Biotech update: several companies trading below fundamental value
Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors.